23 Neurological Conditions

One test. 23 conditions.

Published literature supports digitized spiral analysis as an objective, quantitative endpoint across these neurological conditions. NeuroQuantix standardizes this evidence base into a regulatory-grade platform that delivers pre-specified endpoints for your specific indication. Each condition produces a characteristic kinematic signature that objective measurement can identify and quantify.

Built on 300+ peer-reviewed studies spanning more than three decades of research. Our scoping review of 120 studies in Movement Disorders Clinical Practice maps the full evidence base.

Discuss Your Program Explore 397 kinematic metrics across 12 domains

Published Validation Data

These conditions have the deepest published evidence for digital spiral analysis endpoints, with condition-specific validation studies and quantified performance metrics.

High Reliability

Essential Tremor

High-reliability tremor measurement that complements traditional clinical rating scales. Substantial published evidence base.

Published literature

PD Detection

Parkinson's Disease

Strong PD detection performance and DBS on/off validation. Complementary to MDS-UPDRS for kinematic depth.

Published literature

Differential

Dystonia

Spiral drawing differentiates dystonic from essential tremor. Adds kinematic dimensions to BFMDRS and TWSTRS assessment.

Published literature

Supported by Published Literature

Published literature supports digital spiral analysis for these conditions. NeuroQuantix captures the kinematic signatures that traditional rating scales for each condition cannot objectively measure.

Cerebellar Ataxia

SARA, ICARS

Captures dysmetria, intention tremor, and coordination deficits. The Spiral Width Variability Index (SWVI) shows strong reliability and correlation with SARA/ICARS. Applicable to Friedreich ataxia, spinocerebellar ataxias (SCA), and acquired cerebellar disorders.

NIH/NINDS Overview

Tardive Dyskinesia

AIMS

Quantifies involuntary movement patterns affecting fine motor control. Provides continuous kinematic measurement where the Abnormal Involuntary Movement Scale (AIMS) relies on ordinal clinician ratings. Relevant for VMAT2 inhibitor and second-generation antipsychotic safety monitoring.

NIH/NINDS Overview

Functional (Psychogenic) Tremor

Clinical assessment

Kinematic signatures of functional tremor differ from organic tremor in variability, entrainment, and distractibility patterns. Spiral analysis provides objective markers that support differential diagnosis in clinical trial screening.

Huntington Disease

UHDRS

Captures chorea-related motor disruption, fine motor slowing, and coordination loss in spiral drawing. Relevant for antisense oligonucleotide and gene-silencing trials where the Unified Huntington Disease Rating Scale (UHDRS) composite may lack sensitivity to early motor changes.

NIH/NINDS Overview

Wilson Disease

Unified Wilson Disease Rating Scale

Tremor, dystonia, and motor coordination deficits in Wilson disease produce characteristic kinematic signatures in spiral drawing. Relevant for copper chelation and gene therapy trials targeting hepatolenticular degeneration.

NIH/NINDS Overview

Multiple Sclerosis Tremor

EDSS (motor component)

Intention tremor and dysmetria in MS produce distinct spiral drawing patterns. Kinematic analysis captures the cerebellar and brainstem components of MS-related motor dysfunction that composite disability scales (EDSS) do not isolate.

NIH/NINDS Overview

Full 23-Condition Differential

NeuroQuantix generates differential likelihood profiles across all 23 conditions. Each condition has a characteristic kinematic fingerprint defined by tremor frequency, amplitude modulation, velocity profiles, and pressure dynamics.

Orthostatic Tremor

13-18 Hz

Holmes Tremor

3-5 Hz, rest + intention

Enhanced Physiological Tremor

8-12 Hz

Drug-Induced Parkinsonism

Bradykinesia signature

Primary Writing Tremor

Task-specific activation

Myoclonus

Irregular high-frequency bursts

Myoclonus-Dystonia

Combined signature

Progressive Supranuclear Palsy

Motor slowing + rigidity

FXTAS

Intention tremor + ataxia

Neuropathic Tremor

Variable frequency

Hepatic Encephalopathy

Asterixis + motor slowing

Stroke Recovery

Asymmetric motor recovery

Gene Therapy & Rare Disease Trials

For many neurological gene therapy indications, the global addressable population numbers in the hundreds. Traditional endpoints requiring 50-100 subjects per arm make randomized controlled trials mathematically infeasible.

The solution is not to lower the evidentiary bar. It is to use measurement tools with sufficient precision that smaller samples achieve adequate statistical power.

Continuous kinematic measurement enables powered studies with substantially smaller cohorts than ordinal rating scales typically require. This applies across ET, PD, dystonia, and rare genetic movement disorders targeted by AAV gene therapy, antisense oligonucleotides, and CRISPR-based approaches.

Discuss Your Rare Disease Program

Why Smaller Cohorts Work

Traditional clinician-rated scales sample motor function once per visit on an ordinal grade — the resulting variance demands larger samples to detect treatment effects.

Continuous, high-frequency kinematic measurement captures the same motor task with much greater precision. The variance per measurement drops, the signal-to-noise ratio rises, and the cohort size required to detect a given effect drops with it.

For rare-disease programs where every enrollment slot counts, this measurement-precision lever can determine whether a powered study is feasible at all.

Frequently Asked Questions

How does NeuroQuantix assess 23 different neurological conditions from one test?

Each neurological condition produces a characteristic kinematic signature during spiral drawing: tremor frequency bands, velocity profiles, pressure dynamics, and spatial trajectory patterns differ across conditions. NeuroQuantix applies 82 deterministic diagnostic rules to generate differential likelihood profiles rather than binary classifications. This means the platform identifies which conditions are most consistent with the observed motor patterns.

How does NeuroQuantix work alongside scales like TETRAS, MDS-UPDRS, or SARA?

NeuroQuantix is designed to complement traditional clinician-rated scales (which provide regulatory precedent and clinical interpretability) by adding continuous, high-frequency kinematic measurement. For essential tremor, NeuroQuantix captures tremor frequency and amplitude with high reliability. For Parkinson disease, kinematic metrics isolate domain-specific signals the MDS-UPDRS composite cannot decompose. Many modern trial designs use both — a traditional scale for regulatory continuity, plus digital endpoints to improve sensitivity and increase the probability of detecting real treatment effects.

How does digital spiral analysis support gene therapy and rare disease trials?

Gene therapy and rare disease trials face a fundamental constraint: small patient populations. Continuous kinematic measurement provides substantially higher sensitivity than ordinal scales, which translates to greater statistical power per subject. NeuroQuantix operationalizes published spiral analysis methodology into a regulatory-grade endpoint that makes randomized controlled trials feasible for small populations.

What evidence supports digital spiral analysis for conditions beyond essential tremor and Parkinson disease?

The scoping review published in Movement Disorders Clinical Practice (DOI: 10.1002/mdc3.70278) systematically reviewed 120 studies across 1,407 citations spanning the full body of digitized spiral analysis research. The review identified published validation data across essential tremor, Parkinson disease, cerebellar ataxia, dystonia, multiple sclerosis, stroke, and other conditions. NeuroQuantix addresses the standardization gaps the review identified.